Finnish biotechnology and drug development company moves its drug discovery programme with services in medicinal chemistry and synthesis
Finnish biotechnology and drug development company BioTie Therapies is working with NCE Discovery to move its drug discovery programme forward.
Anne Marjamaki, head of molecular pharmacology at BioTie, explained: "Our main disease focus lies in dependency disorders, inflammation and glycobiology.
We needed the services of NCE Discovery because we don't have any medicinal chemistry or synthesis expertise ourselves." "Initially, we performed a screening programme against a particular target to provide the medicinal chemists from NCE Discovery with weak active compounds.
They used these, along with active structures they found with the help of molecular modelling and database searches, to create the basis for a focused library synthesis programme.
Our aim is to increase the potency of the most promising actives and the plan now is to try to raise this potential even more and proceed to lead optimisation." "We have an excellent working relationship with NCE Discovery and we keep in contact on a regular basis.
Above all, the good communication between us means that work is completed on schedule but there is still some flexibility, even when we need something that is not in the original contract.
We are very pleased that the project with NCE Discovery has been so successful."
